|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pagliuca M, Buonerba C, Fizazi K and Di
Lorenzo G: The evolving systemic treatment landscape for patients
with advanced prostate cancer. Drugs. 79:381–400. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu J, Zheng SL, Komiya A, Mychaleckyj JC,
Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, et
al: Germline mutations and sequence variants of the macrophage
scavenger receptor 1 gene are associated with prostate cancer risk.
Nat Genet. 32:321–325. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jefferies MT, Cox AC, Shorning BY, Meniel
V, Griffiths D, Kynaston HG, Smalley MJ and Clarke AR: PTEN loss
and activation of K-RAS and β-catenin cooperate to accelerate
prostate tumourigenesis. J Pathol. 243:442–456. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suzuki H, Freije D, Nusskern DR, Okami K,
Cairns P, Sidransky D, Isaacs WB and Bova GS: Interfocal
heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic
prostate cancer tissues. Cancer Res. 58:204–209. 1998.PubMed/NCBI
|
|
6
|
Suzuki H, Komiya A, Aida S, Ito H, Yatani
R and Shimazaki J: Detection of human papillomavirus DNA and p53
gene mutations in human prostate cancer. Prostate. 28:318–324.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grignon DJ, Caplan R, Sarkar FH, Lawton
CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA,
et al: p53 status and prognosis of locally advanced prostatic
adenocarcinoma: A study based on RTOG 8610. J Natl Cancer Inst.
89:158–165. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou Z, Flesken-Nikitin A, Corney DC, Wang
W, Goodrich DW, Roy-Burman P and Nikitin AY: Synergy of p53 and Rb
deficiency in a conditional mouse model for metastatic prostate
cancer. Cancer Res. 66:7889–7898. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dong JT, Li CL, Sipe TW and Frierson HF
Jr: Mutations of PTEN/MMAC1 in primary prostate cancers from
Chinese patients. Clin Cancer Res. 7:304–308. 2001.PubMed/NCBI
|
|
10
|
Wang SI, Parsons R and Ittmann M:
Homozygous deletion of the PTEN tumor suppressor gene in a subset
of prostate adenocarcinomas. Clin Cancer Res. 4:811–815.
1998.PubMed/NCBI
|
|
11
|
Lin HK, Hu YC, Lee DK and Chang C:
Regulation of androgen receptor signaling by PTEN (phosphatase and
tensin homolog deleted on chromosome 10) tumor suppressor through
distinct mechanisms in prostate cancer cells. Mol Endocrinol.
18:2409–2423. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nelson PS: Molecular states underlying
androgen receptor activation: A framework for therapeutics
targeting androgen signaling in prostate cancer. J Clin Oncol.
30:644–646. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Yang S, Chen X, Stauffer S, Yu F,
Lele SM, Fu K, Datta K, Palermo N, Chen Y, et al: The hippo pathway
effector YAP regulates motility, invasion, and castration-resistant
growth of prostate cancer cells. Mol Cell Biol. 35:1350–1362. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Noh MG, Kim SS, Hwang EC, Kwon DD and Choi
C: Yes-associated protein expression is correlated to the
differentiation of prostate adenocarcinoma. J Pathol Transl Med.
51:365–373. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Collak FK, Demir U, Ozkanli S, Kurum E and
Zerk PE: Increased expression of YAP1 in prostate cancer correlates
with extraprostatic extension. Cancer Biol Med. 14:405–413. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin X, Zhao W, Zhou P and Niu T: YAP
knockdown inhibits proliferation and induces apoptosis of human
prostate cancer DU145 cells. Mol Med Rep. 17:3783–3788.
2018.PubMed/NCBI
|
|
17
|
Porazinski S, Wang H, Asaoka Y, Behrndt M,
Miyamoto T, Morita H, Hata S, Sasaki T, Krens SFG, Osada Y, et al:
YAP is essential for tissue tension to ensure vertebrate 3D body
shape. Nature. 521:217–221. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qiao Y, Chen J, Lim YB, Finch-Edmondson
ML, Seshachalam VP, Qin L, Jiang T, Low BC, Singh H, Lim CT, et al:
YAP regulates actin dynamics through ARHGAP29 and promotes
metastasis. Cell Rep. 19:1495–1502. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dupont S, Morsut L, Aragona M, Enzo E,
Giulitti S, Cordenonsi M, Zanconato, Le Digabel J, Forcato M,
Bicciato S, et al: Role of YAP/TAZ in mechanotransduction. Nature.
474:179–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Goulding H, Pinder S, Cannon P, Pearson D,
Nicholson R, Snead D, Bell J, Elston CW, Robertson JF, Blamey RW,
et al: A new immunohistochemical antibody for the assessment of
estrogen receptor status on routine formalin-fixed tissue samples.
Hum Pathol. 26:291–294. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ishibashi H, Suzuki T, Suzuki S, Moriya T,
Kaneko C, Takizawa T, Sunamori M, Handa M, Kondo T and Sasano H:
Sex steroid hormone receptors in human thymoma. J Clin Endocrinol
Metab. 88:2309–2317. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pirker R, Pereira JR, von Pawel J,
Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE,
Paz-Ares L, Störkel S, et al: EGFR expression as a predictor of
survival for first-line chemotherapy plus cetuximab in patients
with advanced non-small-cell lung cancer: Analysis of data from the
phase 3 FLEX study. Lancet Oncol. 13:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kawakami T, Takeuchi S, Arimura Y and Soma
Y: Elevated antilysosomal-associated membrane protein-2 antibody
levels in patients with adult Henoch-Schönlein purpura. Br J
Dermatol. 166:1206–1212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pan Z, Tian Y, Zhang B, Zhang X, Shi H,
Liang Z, Wu P, Li R, You B, Yang L, et al: YAP signaling in gastric
cancer-derived mesenchymal stem cells is critical for its promoting
role in cancer progression. Int J Oncol. 51:1055–1066. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen D, Sun Y, Wei Y, Zhang P, Rezaeian
AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC, et al:
LIFR is a breast cancer metastasis suppressor upstream of the
Hippo-YAP pathway and a prognostic marker. Nat Med. 18:1511–1517.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lamar JM, Stern P, Liu H, Schindler JW,
Jiang ZG and Hynes RO: The Hippo pathway target, YAP, promotes
metastasis through its TEAD-interaction domain. Proc Natl Acad Sci
USA. 109:E2441–E2450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST,
Chen J, Poon RT, Zender L, Lowe SW, Hong W, et al: AXL receptor
kinase is a mediator of YAP-dependent oncogenic functions in
hepatocellular carcinoma. Oncogene. 30:1229–1240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang M, Zhao Y, Zhang Y, Wang D, Gu S,
Feng W, Peng W, Gong A and Xu M: LncRNA UCA1 promotes migration and
invasion in pancreatic cancer cells via the Hippo pathway. Biochim
Biophys Acta Mol Basis Dis. 1864:1770–1782. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hsu PC, Miao J, Huang Z, Yang YL, Xu Z,
You J, Dai Y, Yeh CC, Chan G, Liu S, et al: Inhibition of
yes-associated protein suppresses brain metastasis of human lung
adenocarcinoma in a murine model. J Cell Mol Med. 22:3073–3085.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jin D, Guo J, Wang D, Wu Y, Wang X, Gao Y,
Shao C, Xu X and Tan S: The antineoplastic drug metformin
downregulates YAP by interfering with IRF-1 binding to the YAP
promoter in NSCLC. EBioMedicine. 37:188–204. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tcherkezian J and Lamarche-Vane N: Current
knowledge of the large RhoGAP family of proteins. Biol Cell.
99:67–86. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fang Y, Zhu X, Wang J, Li N, Li D, Sakib
N, Sha Z and Song W: MiR-744 functions as a proto-oncogene in
nasopharyngeal carcinoma progression and metastasis via
transcriptional control of ARHGAP5. Oncotarget. 6:13164–13175.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu Q, Lin X, Ding L, Zeng Y, Pang D,
Ouyang N, Xiang Y and Yao H: ARHGAP42 promotes cell migration and
invasion involving PI3K/Akt signaling pathway in nasopharyngeal
carcinoma. Cancer Med. 7:3862–3874. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang L, Shen S, Wang M, Ding F, Xiao H, Li
G and Hu F: Rho GTPase activating protein 24 (ARHGAP24) silencing
promotes lung cancer cell migration and invasion by activating
β-catenin signaling. Med Sci Monit. 25:21–31. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dai X, Geng F, Dai J, Li M and Liu M: Rho
GTPase activating Protein 24 (ARHGAP24) regulates the anti-cancer
activity of sorafenib against breast cancer MDA-MB-231 cells via
the signal transducer and activator of transcription 3 (STAT3)
signaling pathway. Med Sci Monit. 24:8669–8677. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Uehara S, Saito K, Asami H and Ohta Y:
Role of ARHGAP24 in ADP ribosylation factor 6 (ARF6)-dependent
pseudopod formation in human breast carcinoma cells. Anticancer
Res. 37:4837–4844. 2017.PubMed/NCBI
|
|
38
|
Zhang S, Sui L, Zhuang J, He S, Song Y, Ye
Y and Xia W: ARHGAP24 regulates cell ability and apoptosis of
colorectal cancer cells via the regulation of P53. Oncol Lett.
16:3517–3524. 2018.PubMed/NCBI
|
|
39
|
Kaighn ME, Narayan KS, Ohnuki Y, Lechner
JF and Jones LW: Establishment and characterization of a human
prostatic carcinoma cell line (PC-3). Invest Urol. 17:16–23.
1979.PubMed/NCBI
|
|
40
|
Mitchell S, Abel P, Ware M, Stamp G and
Lalani E: Phenotypic and genotypic characterization of commonly
used human prostatic cell lines. BJU Int. 85:932–944. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Y, Song T, Chen Z, Wang Y, Zhang J and
Wang X: Pancreatic stellate cells activation and matrix
metallopeptidase 2 expression correlate with lymph node metastasis
in pancreatic carcinoma. Am J Med Sci. 357:16–22. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Maekawa R, Maki H, Yoshida H, Hojo K,
Tanaka H, Wada T, Uchida N, Takeda Y, Kasai H, Okamoto H, et al:
Correlation of antiangiogenic and antitumor efficacy of N-biphenyl
sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active,
selective matrix metalloproteinase inhibitor. Cancer Res.
59:1231–1235. 1999.PubMed/NCBI
|
|
43
|
Zhang J, Wang G, Chu SJ, Zhu JS, Zhang R,
Lu WW, Xia LQ, Lu YM, Da W and Sun Q: Loss of large tumor
suppressor 1 promotes growth and metastasis of gastric cancer cells
through upregulation of the YAP signaling. Oncotarget.
7:16180–16193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Trudel D, Fradet Y, Meyer F, Harel F and
Têtu B: Significance of MMP-2 expression in prostate cancer: An
immunohistochemical study. Cancer Res. 63:8511–8515.
2003.PubMed/NCBI
|
|
45
|
Chen PC, Tang CH, Lin LW, Tsai CH, Chu CY,
Lin TH and Huang YL: Thrombospondin-2 promotes prostate cancer bone
metastasis by the up-regulation of matrix metalloproteinase-2
through down-regulating miR-376c expression. J Hematol Oncol.
10:332017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ito Y, Ishiguro H, Kobayashi N, Hasumi H,
Watanabe M, Yao M and Uemura H: Adipocyte-derived monocyte
chemotactic protein-1 (MCP-1) promotes prostate cancer progression
through the induction of MMP-2 activity. Prostate. 75:1009–1019.
2015. View Article : Google Scholar : PubMed/NCBI
|
